Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

 April 24, 2026

BioSpace

Analysts are cautiously optimistic about an IPO rebound for biopharma.

M&A / DealsRespiratoryRead full story

Post navigation

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels →
← Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com